Fresenius SE & Co. KGaA Fresenius SE & Co. KGaA: Fresenius raises its earnings guidance for fiscal year 2026 due to strong operational business performance

Ad-hoc Announcement/
Notification published in accordance with Article 17 Market Abuse Regulation (MAR) Fresenius raises its earnings guidance for fiscal year 2026 due to strong operational business performance Fresenius raises its earnings guidance for fiscal year 2026 due to the strong operating performance of its core businesses. Strong operational performance at Fresenius Kabi and Fresenius Helios, together with improved net interest income, supported earnings development. Based on this performance and the business outlook for the second half of 2026, Fresenius increases its guidance for constant-currency growth in core earnings per share^1,3 for fiscal year 2026 to 10% to 15% (previously 5% to 10%).
Fresenius Group – Business Development in the Second Quarter of 2026
In Q2/26, Group revenue¹ increased organically by 6%^1,2 to €5,864 million.
Group EBIT before special items in Q2/26 amounted to €719 million, an increase of 10% in constant currency. In Q2/26, Group EBIT margin¹ improved by 60 bp yoy to 12.3%.
In Q2/26 Group Core EPS^1,3 rose by 14% in constant currency to €0.83.
Guidance for Fiscal Year 2026¹
Fresenius Group⁴: Fresenius continues to expect organic revenue growth² of 4% to 7% for fiscal year 2026. The guidance for constant-currency growth in core earnings per share³ for fiscal year 2026 is raised to 10% to 15% (previously 5% to 10%).
Assumptions to guidance: The company acknowledges that the prevailing trends of a fast-moving macroeconomic and geopolitical environment continue, resulting in increased volatility and a higher level of operational uncertainty. The guidance does not take into account potential extreme scenarios that could affect the company, its peers, and the healthcare sector as a whole.
Revenue and earnings expectations of the operating companies¹
Fresenius Kabi⁵: For fiscal year 2026 organic revenue growth² is expected to be in the mid- to high-single-digit percentage range. EBIT margin is now expected to be at the upper end of the 16.5% to 17.0% range.
Fresenius Helios⁶: For fiscal year 2026 organic revenue growth is expected to be in the mid-single-digit percentage range and EBIT margin of 10.0% to 10.5%.
Footnotes
¹ Before special items
² Organic growth rate adjusted for accounting effects related to Argentina hyperinflation
³ Excluding Fresenius Medical Care and Vitrea
⁴ 2025 base: €22,554 million (revenue), €2.87 (Core EPS)
⁵ 2025 base: €8,612 million (revenue) and €1,413 million (EBIT)
⁶ 2025 base: €13,550 million (revenue) and €1,328 million (EBIT)
Information on the performance indicators is available on our website at https://www.fresenius.com/alternative-performance-measures.
Fresenius SE & Co. KGaA,
represented by Fresenius Management SE,
The Management Board
Bad Homburg v.d.H., August 4, 2026
Person responsible for the notification:
Nick Stone
Senior Vice President Investor Relations
Head of Investor Relations
T: +49 (0) 6172 608-97033
nick.stone@fresenius.com
End of note